Evidence·Exposure / Absorption
ReportedBioavailability evidence
ATLXM0045271
A single reference-linked measurement — its measured value, assay/model context, and interpretation layer kept separate.
Stack
ATLXM0045271
A single reference-linked measurement — its measured value, assay/model context, and interpretation layer kept separate.
ATLXM0045271
Lanreotide forms a drug depot at the site of injection; therefore, there are 2 phases that describe the absorption of Lanreotide: 1. Initial rapid subcutaneous release during the first few days of treatment where drug that has not precipitated is rapidly absorbed. 2. Slow release of drug from the depot via passive diffusion. Absorption is independent of body weight, gender, and dosage.
This page treats the row as evidence attached to an endpoint and assay context. The layer describes how the row can be interpreted; it is not a safety or developability score by itself.
